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Introduction: SYSVAC is an online bibliographic database of systematic reviews and systematic review
protocols on vaccines and immunisation compiled by the London School of Hygiene & Tropical
Medicine and hosted by the World Health Organization (WHO) through their National Immunization
Technical Advisory Groups (NITAG) resource centre (www.nitag-resource.org). Here the development
of the database and a bibliometric review of its content is presented, describing trends in the publication
of policy-relevant systematic reviews on vaccines and immunisation from 2008 to 2016.
Materials and methods: Searches were conducted in seven scientific databases according to a standardized
search protocol, initially in 2014 with the most recent update in January 2017. Abstracts and titles were
screened according to specific inclusion criteria. All included publications were coded into relevant cat-
egories based on a standardized protocol and subsequently analysed to look at trends in time, topic, area
of focus, population and geographic location.
Results: After screening for inclusion criteria, 1285 systematic reviews were included in the database.
While in 2008 there were only 34 systematic reviews on a vaccine-related topic, this increased to 322
in 2016. The most frequent pathogens/diseases studied were influenza, human papillomavirus and pneu-
mococcus. There were several areas of duplication and overlap.
Discussion: As more systematic reviews are published it becomes increasingly time-consuming for
decision-makers to identify relevant information among the ever-increasing volume available. The risk
of duplication also increases, particularly given the current lack of coordination of systematic reviews
on vaccine-related questions, both in terms of their commissioning and their execution. The SYSVAC
database offers an accessible catalogue of vaccine-relevant systematic reviews with, where possible
access or a link to the full-text.
Conclusions: SYSVAC provides a freely searchable platform to identify existing vaccine-policy-relevant
systematic reviews. Systematic reviews will need to be assessed adequately for each specific question
and quality.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2255
2. Material and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2255
2.1. Development of the SYSVAC database . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2255
2.2. Data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2256
3. Results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2256
3.1. Search results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2256
3.2. Most relevant journals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2256
https://doi.org/10.1016/j.vaccine.2018.02.049
0264-410X/ 2018 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author at: London School of Hygiene & Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SH, UK.
E-mail address: silke.fernandes@lshtm.ac.uk (S. Fernandes).
Vaccine 36 (2018) 2254–2261
Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vaccine
3.3. Trends over time . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2256
3.4. Disease/pathogen areas. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2257
3.5. Topic area . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2257
3.6. Geography and country income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2258
3.7. Population focus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2258
3.8. Repetition and overlap of reviews . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2258
4. Discussion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2258
5. Conclusions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2260
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2260
Conflict of interest. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2260
Appendix A. Supplementary material . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2261
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2261
1. Introduction
The global landscape of immunisation has changed consider-
ably during the past two decades. New and considerably more
expensive vaccines are becoming increasingly available in high-
income countries (HIC) while adoption patterns are accelerating
in low- and middle-income countries (LMIC). In LMIC this has been
aided by substantial donor support, such as funds from Gavi, the
Vaccine Alliance, for both strengthening the Expanded Programme
for Immunisation (EPI) and for adopting new and underutilised
vaccines [1]. However, decision-makers in both HIC and LMIC face
an array of questions about which vaccines to prioritise given their
limited budgets. WHO recommends that national vaccine policy is
guided by National Immunisation Technical Advisory Groups
(NITAGs) [2]. However, NITAGs also face difficulties in assimilating
an ever-increasing amount of information. Hence, the need for col-
lating and synthesising the available evidence to support decision-
making in vaccine-related policy.
During the past decade, the number of scientific research arti-
cles and systematic reviews on vaccines has risen substantially.
Consequently, there is a need for tools to filter this evidence and
present it on an accessible platform. Systematic reviews are a par-
ticularly efficient means of summarising evidence for decision-
makers because they use clear, transparent methods for combining
evidence from multiple studies. This means decision-makers do
not need to identify, appraise and synthesise findings from numer-
ous individual studies themselves [3]. Systematic reviews aim to
answer specific questions in order to minimise bias and present
pre-filtered evidence for researchers and decision-makers [4,5].
At present, systematic reviews on vaccine-related questions are
not coordinated, either in terms of commissioning or dissemina-
tion. Unless decision-makers specifically commission a review,
there is currently no process to ensure that proposed systematic
review topics respond to their information needs, which may differ
from one decision-maker to another. This not only leads to gaps in
knowledge if particular questions are neglected, but also to dupli-
cation and overlap. Therefore, many NITAGs commission reviews
to inform them, which leads to duplication [6–11]. At present,
there is no common understanding of what vaccine-relevant sys-
tematic reviews have, or have not, been conducted. It is therefore
unclear where duplication is a risk, or which areas have been
neglected. Ideally, NITAGs should be able to ensure prior to com-
missioning that no similar reviews are planned, ongoing or have
been published.
To date there is no singe repository where decision-makers can
find systematic reviews conducted on topics relevant to vaccina-
tion policy. Identifying reviews on a specific topic requires time,
skills in literature searching and access to academic databases. To
facilitate this, the London School of Hygiene and Tropical Medicine,
with funding from the National Institute for Health Research
(NIHR), has created a database of vaccine policy-relevant system-
atic reviews (including both completed reviews and protocols)
(SYSVAC). The database is hosted by the World Health Organiza-
tion (WHO), who took over the NITAG resource centre (www.
nitag-resource.org) from the Agence de Médicine Préventive
(AMP) and is updated quarterly.
This paper presents a bibliometric analysis of the reviews
included in this database. Bibliometric analysis aims to quantita-
tively characterise the literature, rather than to examine its find-
ings [12]. The objectives of this paper are: (i) to describe the
development of the SYSVAC database, (ii) to provide an overview
of the vaccine-related systematic review literature by describing
the trends in time, topic, area of focus, population and geographic
location of published systematic reviews relevant to vaccine policy
published between 1 January 2008 and 31 December 2016.
2. Material and methods
In the remaining text the word systematic review will be used
for both completed systematic reviews as well as systematic
review protocols.
2.1. Development of the SYSVAC database
Systematic reviews on vaccine- and immunization-related
topics were identified through searches carried out in MEDLINE,
Embase, the Cochrane Library (systematic reviews and Health
Technology Assessments only), Scopus, Web of Science, Global
Health and the PROSPERO International prospective register of sys-
tematic reviews [13]. PROSPERO is unique in that it includes the
description of not only completed but also ongoing and planned
systematic reviews. The final search was conducted in January
2017. Search terms specific to vaccines and immunisation were
combined with filters designed to retrieve systematic reviews.
The entries were restricted to a publication date from 1 January
2000 to 31 January 2017. Vaccine-related search terms were
adapted to each database from the filters used in the National Insti-
tute of Health and Care Excellence Guidelines PH21 [14]. Search fil-
ters specific to systematic reviews were adapted from the
Canadian Agency for Drugs and Technologies in Health strategy
for searches on the Ovid platform [15] in the initial search. How-
ever, for the updates, the more specific BMJ search filter was used
for Medline and Embase [16] and adapted for the other databases.
The reason for this change was that the updates aimed to retrieve
the more recent systematic reviews only, so a broader filter was no
longer needed. In contrast to the early days of systematic review-
ing, when a range of terms may have been used to describe the
method, there is now a greater consensus on how to present, report
and describe systematic reviews so omitting less specific terms
does not lead to a loss in sensitivity. Wherever possible, searches
were limited to title, keyword and abstract fields and to research
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involving human subjects. The full list of search terms used for
each database can be found in supplementary file 1.
For each set of search results, duplicate references were
removed and titles and abstracts were screened using pre-
defined inclusion criteria. To be included in the database, articles
had to meet the following criteria: (1) be a systematic review;
(2) focus on human subjects; (3) focus on preventive vaccines,
rather than vaccines for treatment or immunotherapy; (4) have a
publication date on or after 1st January 2008 (see supplementary
file 1 for more details). In addition, the analysis presented here is
restricted to reviews published on or before the 31st of December
2016. (5) Not focus on vaccine development; and (6) not be with-
drawn. Full texts of the papers were not retrieved during the
screening. All systematic reviews meeting the inclusion criteria
were combined into one Endnote database (Thomson Reuters
2014) and duplicates were removed.
Because of the size of the database, all entries were indexed
using keywords for ease of categorisation. A keyword coding proto-
col was developed, pre-tested and refined by two researchers (SF
and HB), with input from staff at AMP. Keywords enabled entries
to be assigned to categories in five areas: (1) pathogen or disease,
e.g. varicella; (2) target population, e.g. adolescents, pregnant
women; (3) geographical location according to WHO regions
[17]; (4) country income group according to the World Bank list
of economies published July 2015 [18] and (5) topic area, e.g.
immunology. An exhaustive list of all keywords can be found in
supplementary file 1. Keywords were not mutually exclusive and
articles could be classified with multiple keywords or none from
each category. Any queries during the screening and coding pro-
cess were resolved by consensus between two researchers (SF
and HB).
2.2. Data analysis
The database content was exported from Endnote X7 to Excel
2016. Data classifications were checked and cleaned. The database
was analysed by year of publication, journal and keywords. Trends
over time were explored for the disease/pathogen keyword cate-
gory. As a comparison to general biomedical research output, we
explored the number of records published in PubMed per year in
general and records containing ‘‘systematic review” in title or
abstract. Further we examined annual numbers of systematic
reviews registered in Prospero (a systematic review register
launched in 2011) in general and records containing ‘vaccin⁄’ or
‘immuni⁄’ in title/abstract or keywords.
For the main disease/pathogen and topic areas, titles and
abstracts were compared to ascertain any two or more reviews
on identical or overlapping topics.
3. Results
3.1. Search results
All searches combined identified 29,078 references. After
removing duplicates, 15,064 records remained and after screening,
1285 unique systematic reviews and protocols were included in
the database and analysis. The full details are shown in the PRISMA
flow diagram in Fig. 1.
* of which 37 were systematic review protocols
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Fig. 1. Flow of references from initial search to inclusion in database.
2256 S. Fernandes et al. / Vaccine 36 (2018) 2254–2261
3.2. Most relevant journals
The 1285 unique systematic reviews were published in 398
separate academic journals as well as the Cochrane databases,
most commonly ‘‘Vaccine” (N = 153) and the ‘‘Cochrane systematic
review database” (N = 82).
3.3. Trends over time
The number of systematic reviews identified per year on
vaccine-related topics increased steadily from 34 in 2008 to 322
in 2016 (see Fig. 2), a more than ninefold increase. During the same
period the total number of articles indexed on PubMed increased
by 50% from 835,946 in 2008 to 1,255,235 in 2016. PubMed
records containing ‘‘systematic review” in either the title or
abstract increased 5-fold from 3456 in 2008 to 17,691 in 2016.
The number of reviews (on any topic) registered on Prospero
increased by almost 30 times from 284 in 2011 to 8162 in 2016.
However, vaccine-related review registrations lagged behind this
general trend, with only three identified in 2011 and 53 in 2016
– an almost 18-fold increase (for more details, see supplementary
file 2.1, Tables S1 and S2).
3.4. Disease/pathogen areas
The database was analysed for 48 specific disease/pathogen
areas ranging alphabetically from Adenovirus to Zika virus (see
supplementary file 1). Table 1 shows the number of systematic
reviews for each disease/pathogen. Out of 1285 systematic
reviews, 312 (24%) were conducted on a general immunisation
topic, while 973 (76%) focused on disease/pathogen specific topics,
of which 859 (88%) concentrated on one disease/pathogen area and
114 (12%) on two or more. For six disease/pathogen areas at least
50 systematic reviews were identified: influenza (N = 260; 20%),
human papilloma virus (HPV) (N = 173; 13%), pneumococcus (N
= 145; 11%), hepatitis B (N = 96; 7%), rotavirus (N = 54; 4%) and
measles (N = 50; 4%). Fig. 3 shows the trend over time for these
six disease/pathogen areas, all of which exhibit a general upwards
trend in the annual number of systematic reviews. The increase in
numbers of systematic reviews was steepest for influenza, HPV and
pneumococcus. Annual numbers of systematic reviews for hepati-
tis B seem to have plateaued in the past two years. On the other
hand, there appears to have been a sharp increase in measles sys-
tematic reviews in 2016. For influenza, there is a peak in the years
2012 and 2013, shortly after the 2009/2010 H1N1 pandemic; the
N=1285
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Fig. 2. Number of systematic reviews on vaccination/immunization by year.
Table 1
Number of systematic reviews by disease/pathogen.
Disease/pathogen specific estimates
Disease/pathogen area Quantity % of
total
Influenza 260 20%
Human papillomavirus 173 13%
Pneumococcus 145 11%
Hepatitis B 96 7%
Rotavirus 54 4%
Measles 50 4%
Pertussis 49 4%
Tetanus toxoid 41 3%
Varicella 37 3%
Tuberculosis 35 3%
Rubella 33 3%
Haemophilus influenzae type b (Hib) 32 2%
Poliomyelitis 29 2%
Herpes zoster 26 2%
Diptheria 25 2%
Mumps 23 2%
Combination vaccine 19 1%
Hepatitis A 18 1%
Meningococcal infection 16 1%
Cholera 11 1%
Yellow fever 10 1%
Dengue 8 1%
Malaria, Rabies 7 1%
Smallpox 6 <1%
Escherichia coli, HIV (each) 5 <1%
Japanese encephalitis 4 <1%
Hepatitis C, Leishmaniasis, Salmonella (each) 3 <1%
Adenovirus, Anthrax, Coxiella burnetii (Q fever), Ebola,
Shigella, Tick-borne encephalitis, Typhoid (each)
2 <1%
Campylobacter, Enterovirus vaccine (hand foot and
mouth), Herpes simplex, Mycobacterium leprae,
Mycobacterium vaccae, Pseudomonas aeruginosa,
Respiratory Syncytial Virus (RSV), Streptococcus group
B (each)
1 <1%
Summary estimates
All systematic reviews 1285 100%
On general vaccination/immunization topic 312 24%
On disease-specific topic 973 76%
On one disease/pathogen area 859 67%
On two or more disease/pathogen area 114 9%
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time lag may reflect the time taken to commission, conduct and
publish systematic reviews.
3.5. Topic area
Fig. 4 shows the number of systematic reviews by topic area. A
large number focused on epidemiology (N = 537, 42%), safety/pain
(N = 414, 32%) and immunology (N = 281, 22%). These topic areas
were followed by coverage (N = 225, 18%), economic studies (N =
147, 11%) and knowledge, attitude, behaviour & acceptability (N
= 113, 9%).
3.6. Geography and country income
Most reviews did not focus on a specific region of the world (N
= 1096, 85%). Out of the 189 (15%) articles with a geographical
focus, 171 (90%) concentrated on one specific region and 18
(10%) on more than one specific region. Of the 189 systematic
reviews with a geographical restriction, the commonest target
was Europe with 61 (32%) articles, followed by Western Pacific
and the Americas with 45 (24%) and 51 (27%) articles, respectively.
Lastly, a smaller number of reviews focused on Africa and South-
East Asia (both N = 24, 13%), as well as the Eastern Mediterranean
region (N = 16, 8%) (see Fig. S1 in supplementary file 2).
The majority of reviews (N = 1061, 83%) were not restricted to a
specific country income group. Of the 224 (17%) reviews that had
this focus, 145 (65%) concentrated on one and 79 (35%) on more
than one country income group, with 121 (54%) focusing on
middle-income countries, 105 (47%) on high-income countries
and 83 (37%) on low-income countries (see Fig. S2 in supplemen-
tary file 2).
3.7. Population focus
Reviews focused on different age groups and specific popula-
tions of interest. A total of 524 (41%) reviews did not specify any
focal population group, while 504 (39%) focused on one group,
and 257 (20%) on more than one particular population group.
Fig. 5 shows that the most common focal age group was 0–9 years
(N = 369, 29%). Eleven percent (N = 146) of reviews focused on
adults, 8% (N = 101) on 10–18 year olds and 5% (N = 69) on older
adults aged 65 or more. Other focal populations included risk
groups (N = 189, 15%), health care workers (N = 76, 6%), parents/
care givers (N = 73, 6%), and pregnant women (N = 62, 5%).
3.8. Repetition and overlap of reviews
There appeared to be a number of overlapping review topics. To
highlight some of them, we looked at reviews on influenza and
HPV in more detail. Among 260 systematic reviews looking at
influenza, 17 focused on influenza vaccination during pregnancy
and 13 of these looked at safety and adverse birth outcomes, ten
at efficacy or effectiveness and two at coverage or determinants
of coverage. In the year 2015, four systematic reviews were con-
ducted on almost identical topics looking at the association
between maternal influenza vaccination and negative birth out-
comes, including stillbirth, spontaneous abortion, fetal death, pre-
term delivery and congenital malformation [19–22]. Thirty-six
systematic reviews published between 2009 and 2016 looked at
influenza vaccination among health care workers, 27 of which
focused on uptake and its determinants as well as attitudes
towards influenza vaccination and 17 on safety, efficacy or effec-
tiveness outcomes. Out of the 173 reviews found on HPV, 28
reported on economic outcomes, with 16 synthesizing evidence
on the cost-effectiveness of HPV vaccine when targeting females.
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There was also a substantial overlap of reviews in other topic areas
of HPV vaccination, including epidemiology, immunology, safety,
coverage and knowledge, attitudes & behaviour.
4. Discussion
The analyses presented in this paper show the substantial
growth of systematic reviews on vaccine research during the past
nine years, with annual numbers increasing more than ninefold
from 2008 to 2016. Several factors may have contributed to this
increase. Expansion in primary research may have augmented
the number of potential systematic reviews. Over the past decade,
a greater interest in vaccine research has developed, supported by
more research funding [1,23], as well as broader availability of vac-
cines worldwide. Systematic reviews have become an increasingly
popular method, with more being conducted in all fields, not just
on vaccines. This may be the result of a wider recognition of the
value of systematic reviews. While the annual number of records
in PubMed containing the term ‘‘systematic review” has grown at
a similar rate to the numbers in our database (130% and 145% aver-
age annual increase), the increase in output of general biomedical
research was at a slower speed (106% average annual increase).
The ‘‘Prospero” database, which registers systematic reviews, has
seen an almost exponential increase (260% average annual
increase) in numbers of annual records from 2011, the year of its
inception, to 2016. However, it appears that vaccine-related
records on Prospero increased at a slower rate (210% average
annual increase), suggesting the recent popularity of systematic
reviews as the primary driver of the annual increase in records
on our database, rather than the more modest increase in
vaccine-related literature. While there are now a large number of
vaccine-relevant systematic reviews available or planned, it never-
theless seems that the field has a smaller secondary research out-
put than other health-related topics.
As more systematic reviews are being conducted, the potential
for duplication and overlap rises. We found numerous examples of
reviews in very similar areas in the field of vaccination. Given the
considerable time, effort and resources required to conduct a sys-
tematic review, such apparent duplication may be an inefficient
use of resources. Before commencing a systematic review, as a first
step to avoid duplication, reviewers should ideally confirm that
there are no currently planned or completed systematic reviews
on a similar topic using Prospero or SYSVAC. Thereafter, the com-
missioning NITAGs or the reviewers themselves should register
their systematic review on Prospero at the start of their undertak-
ing. A risk of duplication still exists for reviews that are planned or
ongoing, but have not been registered on Prospero, because SYS-
VAC would only capture them in the next update following publi-
cation. More widespread use of Prospero and SYSVAC could
improve efficiency, obviate duplication and potentially facilitate
pooling of resources. Equally important to transparent planning
of systematic reviews is choosing topics wisely and purposively.
Decision-makers often lack crucial evidence required to support
or reject policies. Systematic reviews can be of great use in the
decision-making process, but without coordination and differenti-
ation between researchers, funders and decision-makers, resources
will not be used efficiently. Improving communication among the
different stakeholders will increase efficiency. Key figures from dif-
ferent stakeholder groups could then develop a process to reach
consensus about which review topics to pursue. A starting point
would be to use the SYSVAC database and Prospero to identify
which reviews have already been conducted or are planned. Such
a process might open the possibility of pooling resources and
N=1236; 49 systematic reviews did not specify a topic area in abstract or title
* Epidemiology includes systematic reviews on vaccine effects against microbiological or epidemiological endpoints (eg. infection, disease, mortality) 
and impact on disease epidemiology (including indirect effects and impact on serotype distribution)
** Immunology includes systematic reviews on vaccine effects against immune markers or other biological endpoints (eg. antibodies, immune cells, cytokines)
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collaborations among different groups. The involvement of
decision-makers in topic selection should help ensure the topics
are of use to them, which would ultimately benefit the people
and communities being studied.
The SYSVAC database and this bibliometric analysis have a
number of limitations. Firstly, while decision makers will easily
be able to identify relevant systematic reviews on SYSVAC, they
will still need to conduct a thorough quality assessment of each
review, followed by a synthesis of all reviews applicable to their
specific question. Currently, there are a number of tools available
to appraise the quality of systematic reviews. The PRISMA [24]
and AMSTAR [25] checklists are well-known and tested tools to
assess methodological quality of systematic reviews. However, to
appraise the quality or relevance of a systematic review a broader
framework is needed. The US Agency for Health Care Research and
Quality has proposed a five-step approach for identifying, apprais-
ing relevance and methodological quality, analysing and using
existing systematic reviews [26]. In addition to following the
guidelines and checklists mentioned above, it is essential to
involve experts in the field to translate review results into policy.
Secondly, while the present analysis identified a number of
overlaps in review topics, it is unclear to what extent the method-
ology and results of these reviews are similar, as we only screened
and coded based on the title and abstract. The user would need to
assess this based on the specific question asked and scrutinize both
methods and results of any reviews retrieved.
Decision-makers need to find systematic reviews easily if they
are to use them. The SYSVAC database (www.nitag-resource.org)
is a freely available online database of vaccine-relevant systematic
reviews aimed at decision-makers as a resource for quick refer-
ence, information and guidance. It should increase the ease with
which vaccine-relevant systematic reviews can be identified so
that decisions can be based on the best available evidence to max-
imise population health outcomes.
5. Conclusions
From 2008 to 2016 the number of vaccine-related systematic
reviews published annually increased by over 9 times. There
appears to be large potential for duplication, which could be
reduced if intentions to conduct a systematic review were regis-
tered prospectively and existing reviews were searched prior to
new review commissioning. Decision-makers can use the SYSVAC
database (www.nitag-resource.org) to search for systematic
reviews on vaccine-related topics to inform their decision-
making. The SYSVAC database could also be used as the focal point
for the coordination of the commissioning of systematic reviews
and the removal of duplication and inefficiency in evidence synthe-
sis for vaccine policy.
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